Homozygous deletion of the MTAP gene is frequently (~ 40%) seen in lung cancer patients [30], and leads to elevated levels of MTA, a metabolite known to act as an endogenous inhibitor of PRMT5 activity [31–33]. This evidence concerns the gene MTAP and lung cancer.